The Cell Cycle Checkpoint Gene, RAD17 rs1045051, Is Associated with Prostate Cancer Risk

Jingkai Sun, Wenfeng Lin, Qixu Wang, Akiko Sakai, Ruizhi Xue, Masami Watanabe, Chunxiao Liu, Takuya Sadahira, Yasutomo Nasu, Abai Xu, Peng Huang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Human RAD17, as an agonist of checkpoint signaling, plays an essential role in mediating DNA damage. This hospital-based case-control study aimed to explore the association between RAD17 rs1045051, a missense single nucleotide polymorphism (SNP), and prostate cancer risk. Subjects were 358 prostate cancer patients and 314 cancer-free urology patients undergoing treatment at the Zhujiang Hospital of Southern Medical University in China. RAD17 gene polymorphism rs1045051 was evaluated by the SNaPshot method. Compared with the RAD17 gene polymorphism rs1045051 AA genotype, there was a higher risk of prostate cancer for the CC genotype (adjusted odds ratio [AOR]=1.731, 95% confidence interval [95%CI]=1.031−2.908, p=0.038). Compared with the A allele, the C allele was significantly associated with the disease status (AOR=1.302, 95%CI=1.037−1.634, p=0.023). All these findings indicate that in the SNP rs1045051, both the CC genotype and C allele may have a substantial influence on the prostate cancer risk.

Original languageEnglish
Pages (from-to)415-421
Number of pages7
JournalActa medica Okayama
Issue number4
Publication statusPublished - 2021


  • RAD17
  • cell cycle checkpoint
  • prostate cancer
  • rs1045051
  • single-nucleotide polymorphisms

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'The Cell Cycle Checkpoint Gene, RAD17 rs1045051, Is Associated with Prostate Cancer Risk'. Together they form a unique fingerprint.

Cite this